Solutions

Early Phase
Development

Accelerating your journey from discovery to clinical validation with precision-engineered assays and strategic biomarker integration.

Purpose-Built for Early Phase Complexity

Early-phase development is where critical decisions shape a program's future. Missed biomarker insights, suboptimal dose-escalation strategies, or regulatory setbacks can significantly impact timelines.

Our purpose-built infrastructure helps generate reliable data, reduce risk, and support confident, evidence-based decisions from the very first stages of development—bridging the translational gap between science and clinical success.

Core Capabilities

Discovery Integration

Seamless transition of discovery assays into robust, clinical-grade testing to validate early targets and establish proof of mechanism.

Clinical Execution

Agile clinical operations tailored for early-phase environments, ensuring rapid patient enrollment, stringent monitoring, and superior data quality.

Regulatory Navigation

Expert guidance through complex global regulatory pathways, minimizing approval hurdles for IND/CTA submissions and protocol designs.

First-in-Human (FIH) Development Excellence

Executing FIH studies requires extraordinary precision and agility. We provide end-to-end expertise designed to safeguard patient safety while rapidly evaluating pharmacokinetics and preliminary efficacy.

Clinical Trial Design

Custom, risk-mitigated protocols optimizing subject enrollment and safety monitoring.

Adaptive Development Strategies

Real-time data review to inform dose-escalation and cohort expansion efficiently.

Integrated Biomarker Support

Laboratory capabilities tightly woven into clinical operations for rapid decision-making.

Therapeutic Expertise

Deep scientific knowledge across the most challenging and innovative therapeutic areas.

Oncology

Rare Diseases

Cell & Gene Therapy

Precision Medicine

The Development Journey

Our comprehensive roadmap from target validation to clinical proof of concept.

01

Target Validation

02

Preclinical Development

03

FIH Studies

04

Dose Escalation

05

Phase 2 Readiness

150+
FIH Studies Completed
40+
Global Clinical Sites
30%
Accelerated Timelines

Success Stories

Demonstrating impact through real-world clinical execution and biomarker integration.

Oncology Dose Escalation
Challenge:Complex PK/PD analysis requirement for a novel immunotherapy.
Result:Accelerated dose determination by 2 months through integrated real-time lab data.
Rare Disease FIH
Challenge:Extremely limited patient population requiring precise biomarker screening.
Result:Successfully enrolled target cohort utilizing our specialized global site network.
Cell Therapy Logistics
Challenge:Time-critical apheresis collection and complex manufacturing transit.
Result:Achieved 100% chain-of-custody compliance with zero logistical deviations.

Frequently Asked Questions

Partner With Us

Life science innovators come to CNC Path Lab

Ready to accelerate your clinical program? Our experts are here to help you design and execute the perfect laboratory strategy. Are you ready?